Privium Fund Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Privium Fund Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.67M	Sell	9,400 -1,955	-17%	-$866K	0.86%	24
2026 Q1	$5.07M	Buy	11,355 +2,000	+21%	+$933K	1.06%	23
2025 Q4	$4.24M	Buy	9,355 +1,055	+13%	+$455K	0.78%	23
2025 Q3	$3.25M	Hold	8,300	–	–	0.58%	24
2025 Q2	$3.75M	Hold	8,300	–	–	0.81%	18
2025 Q1	$4.02M	Buy	+8,300	New	+$3.87M	1.05%	19
2024 Q1	–	Sell	-15,116	Closed	-$6.21M	–	129
2023 Q4	$6.21M	Sell	15,116 -6,279	-29%	-$2.32M	1.73%	19
2023 Q3	$7.44M	Sell	21,395 -9,515	-31%	-$3.33M	2.21%	12
2023 Q2	$10.8M	Sell	30,910 -1,560	-5%	-$526K	3.1%	9
2023 Q1	$10.2M	Sell	32,470 -2,837	-8%	-$851K	3.44%	7
2022 Q4	$10.2M	Buy	35,307 +6,807	+24%	+$2.07M	3.87%	9
2022 Q3	$8.35M	Buy	28,500 +500	+2%	+$144K	3.03%	9
2022 Q2	$7.89M	Hold	28,000	–	–	2.61%	12
2022 Q1	$7.31M	Sell	28,000 -3,000	-10%	-$712K	1.62%	19
2021 Q4	$6.9M	Buy	+31,000	New	+$6.03M	1.37%	24

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Privium Fund Management's VRTX Position: Q2 2026 in Review

Privium Fund Management reduced its Vertex Pharmaceuticals (VRTX) stake by 17% in Q2 2026, selling an estimated $866K and leaving 9,400 shares worth $4.67M. The position accounts for 0.86% of the portfolio, ranked #24.

Privium Fund Management first reported a position in VRTX in Q4 2021 and has held it in 15 quarters since. The position peaked at $10.8M in Q2 2023. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Privium Fund Management held 9,400 shares of Vertex Pharmaceuticals worth $4.67M as of Q2 2026.
Privium Fund Management sold 1,955 Vertex Pharmaceuticals shares in Q2 2026, an estimated $866K.
Vertex Pharmaceuticals made up 0.86% of Privium Fund Management's portfolio in Q2 2026, its #24 holding.
Privium Fund Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 15 quarters since.
Privium Fund Management's Vertex Pharmaceuticals position peaked at $10.8M in Q2 2023.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.